182 related articles for article (PubMed ID: 34099490)
1. Valosin-Containing Protein Stabilizes Mutant p53 to Promote Pancreatic Cancer Growth.
Wang J; Chen Y; Huang C; Hao Q; Zeng SX; Omari S; Zhang Y; Zhou X; Lu H
Cancer Res; 2021 Aug; 81(15):4041-4053. PubMed ID: 34099490
[TBL] [Abstract][Full Text] [Related]
2. The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells.
Butera G; Brandi J; Cavallini C; Scarpa A; Lawlor RT; Scupoli MT; Marengo E; Cecconi D; Manfredi M; Donadelli M
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32526853
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma.
Yamamoto S; Tomita Y; Hoshida Y; Nagano H; Dono K; Umeshita K; Sakon M; Ishikawa O; Ohigashi H; Nakamori S; Monden M; Aozasa K
Ann Surg Oncol; 2004 Feb; 11(2):165-72. PubMed ID: 14761919
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
5.
Maddalena M; Mallel G; Nataraj NB; Shreberk-Shaked M; Hassin O; Mukherjee S; Arandkar S; Rotkopf R; Kapsack A; Lambiase G; Pellegrino B; Ben-Isaac E; Golani O; Addadi Y; Hajaj E; Eilam R; Straussman R; Yarden Y; Lotem M; Oren M
Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34088837
[TBL] [Abstract][Full Text] [Related]
6. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
[TBL] [Abstract][Full Text] [Related]
7. [The relationship and clinicopathological significance of Numb,MDM2 and p53 expression in human pancreatic cancer].
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Zhonghua Wai Ke Za Zhi; 2014 Sep; 52(9):675-81. PubMed ID: 25410780
[TBL] [Abstract][Full Text] [Related]
8. Targeting valosin-containing protein enhances the efficacy of radiation therapy in esophageal squamous cell carcinoma.
Luo H; Song H; Mao R; Gao Q; Feng Z; Wang N; Song S; Jiao R; Ni P; Ge H
Cancer Sci; 2019 Nov; 110(11):3464-3475. PubMed ID: 31454136
[TBL] [Abstract][Full Text] [Related]
9. VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in
Lee YS; Klomp JE; Stalnecker CA; Goodwin CM; Gao Y; Droby GN; Vaziri C; Bryant KL; Der CJ; Cox AD
Genes Cancer; 2023; 14():30-49. PubMed ID: 36923647
[TBL] [Abstract][Full Text] [Related]
10. Disruption of valosin-containing protein activity causes cardiomyopathy and reveals pleiotropic functions in cardiac homeostasis.
Brody MJ; Vanhoutte D; Bakshi CV; Liu R; Correll RN; Sargent MA; Molkentin JD
J Biol Chem; 2019 May; 294(22):8918-8929. PubMed ID: 31006653
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.
Feldmann G; Karikari C; dal Molin M; Duringer S; Volkmann P; Bartsch DK; Bisht S; Koorstra JB; Brossart P; Maitra A; Fendrich V
Cancer Biol Ther; 2011 Jun; 11(11):959-68. PubMed ID: 21455033
[TBL] [Abstract][Full Text] [Related]
12. Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis.
Tiwari A; Tashiro K; Dixit A; Soni A; Vogel K; Hall B; Shafqat I; Slaughter J; Param N; Le A; Saunders E; Paithane U; Garcia G; Campos AR; Zettervall J; Carlson M; Starr TK; Marahrens Y; Deshpande AJ; Commisso C; Provenzano PP; Bagchi A
Gastroenterology; 2020 Nov; 159(5):1882-1897.e5. PubMed ID: 32768595
[TBL] [Abstract][Full Text] [Related]
13. An N
Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
[TBL] [Abstract][Full Text] [Related]
14. ABCC3 is a novel target for the treatment of pancreatic cancer.
Adamska A; Ferro R; Lattanzio R; Capone E; Domenichini A; Damiani V; Chiorino G; Akkaya BG; Linton KJ; De Laurenzi V; Sala G; Falasca M
Adv Biol Regul; 2019 Aug; 73():100634. PubMed ID: 31053501
[TBL] [Abstract][Full Text] [Related]
15. A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer.
Marin-Muller C; Li D; Bharadwaj U; Li M; Chen C; Hodges SE; Fisher WE; Mo Q; Hung MC; Yao Q
Clin Cancer Res; 2013 Nov; 19(21):5901-13. PubMed ID: 23989979
[TBL] [Abstract][Full Text] [Related]
16. Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion.
Guo AK; Itahana Y; Seshachalam VP; Chow HY; Ghosh S; Itahana K
Br J Cancer; 2021 Jan; 124(1):299-312. PubMed ID: 33144694
[TBL] [Abstract][Full Text] [Related]
17. The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.
Muniz VP; Barnes JM; Paliwal S; Zhang X; Tang X; Chen S; Zamba KD; Cullen JJ; Meyerholz DK; Meyers S; Davis JN; Grossman SR; Henry MD; Quelle DE
Mol Cancer Res; 2011 Jul; 9(7):867-77. PubMed ID: 21636682
[TBL] [Abstract][Full Text] [Related]
18. EZH2-shRNA-mediated upregulation of p21waf1/cip1 and its transcriptional enhancers with concomitant downmodulation of mutant p53 in pancreatic ductal adenocarcinoma.
Batchu RB; Qazi AM; Gruzdyn OV; Semaan A; Seward SM; Chamala S; Dhulipala VB; Bouwman DL; Weaver DW; Gruber SA
Surgery; 2013 Oct; 154(4):739-46; discussion 746-7. PubMed ID: 24074410
[TBL] [Abstract][Full Text] [Related]
19. Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.
Abrams SL; Duda P; Akula SM; Steelman LS; Follo ML; Cocco L; Ratti S; Martelli AM; Montalto G; Emma MR; Cervello M; Rakus D; Gizak A; McCubrey JA
Cells; 2022 Feb; 11(5):. PubMed ID: 35269416
[TBL] [Abstract][Full Text] [Related]
20. Preferred binding of gain-of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to multiple binding sites.
Vaughan CA; Deb SP; Deb S; Windle B
Oncotarget; 2014 Jan; 5(2):417-27. PubMed ID: 24481480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
